Heterobimetallic Ru(II)/M (M = Ag+, Cu2+, Pb2+) Complexes as Photosensitizers for Room-Temperature Gas Sensing.

This work is devoted to the investigation of heterobimetallic Ru(II) complexes as photosensitizers for room-temperature photoactivated In2O3-based gas sensors. Nanocrystalline In2O3 was synthesized by the chemical precipitation method. The obtained In2O3 matrix has a single-phase bixbyite structure with an average grain size of 13-14 nm and a specific surface area of 72 ± 3 m2/g. The synthesis of new ditope ligands with different coordination centers, their ruthenium complexes, and the preparation of heterobimetallic complexes with various cations of heavy and transition metals (Ag+, Pb2+, or Cu2+) is reported. The heterobimetallic Ru(II) complexes were deposited onto the surface of the In2O3 matrix by impregnation. The obtained hybrid materials were characterized by X-ray fluorescent analysis, FTIR spectroscopy, and optical absorption spectroscopy. The elemental distribution on the hybrids was characterized by energy-dispersive X-ray spectroscopy (EDS) mapping. The gas sensor properties were investigated toward NO2, NO, and NH3 at room temperature under periodic blue LED irradiation. It was identified that the nature of the second binding cation in Ru(II) heterobimetallic complexes can influence the selectivity toward different gases. Thus, the maximum sensor signal for oxidizing gases (NO2, NO) was obtained for hybrids containing Ag+ or Pb2+ cations while the presence of Cu2+ cation results in the highest and reversible sensor response toward ammonia. This may be due to the specific adsorption of NH3 molecules on Cu2+ cations. On the other hand, Cu2+ ions are proposed to be active sites for the reduction of nitrogen oxides to N2. This fact leads to a significant decrease in the sensor response toward NO2 and NO gases.

The Role of E3 Ligase Pirh2 in Disease.

The p53-dependent ubiquitin ligase Pirh2 regulates a number of proteins involved in different cancer-associated processes. Targeting the p53 family proteins, Chk2, p27Kip1, Twist1 and others, Pirh2 participates in such cellular processes as proliferation, cell cycle regulation, apoptosis and cellular migration. Thus, it is not surprising that Pirh2 takes part in the initiation and progression of different diseases and pathologies including but not limited to cancer. In this review, we aimed to summarize the available data on Pirh2 regulation, its protein targets and its role in various diseases and pathological processes, thus making the Pirh2 protein a promising therapeutic target.

Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery.

The design of effective target-specific drugs for COVID-19 treatment has become an intriguing challenge for modern science. The SARS-CoV-2 main protease, Mpro, responsible for the processing of SARS-CoV-2 polyproteins and production of individual components of viral replication machinery, is an attractive candidate target for drug discovery. Specific Mpro inhibitors have turned out to be promising anticoronaviral agents. Thus, an effective platform for quantitative screening of Mpro-targeting molecules is urgently needed. Here, we propose a pre-steady-state kinetic analysis of the interaction of Mpro with inhibitors as a basis for such a platform. We examined the kinetic mechanism of peptide substrate binding and cleavage by wild-type Mpro and by its catalytically inactive mutant C145A. The enzyme induces conformational changes of the peptide during the reaction. The inhibition of Mpro by boceprevir, telaprevir, GC-376, PF-00835231, or thimerosal was investigated. Detailed pre-steady-state kinetics of the interaction of the wild-type enzyme with the most potent inhibitor, PF-00835231, revealed a two-step binding mechanism, followed by covalent complex formation. The C145A Mpro mutant interacts with PF-00835231 approximately 100-fold less effectively. Nevertheless, the binding constant of PF-00835231 toward C145A Mpro is still good enough to inhibit the enzyme. Therefore, our results suggest that even noncovalent inhibitor binding due to a fine conformational fit into the active site is sufficient for efficient inhibition. A structure-based virtual screening and a subsequent detailed assessment of inhibition efficacy allowed us to select two compounds as promising noncovalent inhibitor leads of SARS-CoV-2 Mpro.

A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice.

As SARS-CoV-2 continues to cause morbidity and mortality around the world, there is an urgent need for the development of effective medical countermeasures. Here, we assessed the antiviral capacity of a minimal RIG-I agonist, stem-loop RNA 14 (SLR14), in viral control, disease prevention, post-infection therapy, and cross-variant protection in mouse models of SARS-CoV-2 infection. A single dose of SLR14 prevented viral infection in the lower respiratory tract and development of severe disease in a type I interferon (IFN-I)-dependent manner. SLR14 demonstrated remarkable prophylactic protective capacity against lethal SARS-CoV-2 infection and retained considerable efficacy as a therapeutic agent. In immunodeficient mice carrying chronic SARS-CoV-2 infection, SLR14 elicited near-sterilizing innate immunity in the absence of the adaptive immune system. In the context of infection with variants of concern (VOCs), SLR14 conferred broad protection against emerging VOCs. These findings demonstrate the therapeutic potential of SLR14 as a host-directed, broad-spectrum antiviral for early post-exposure treatment and treatment of chronically infected immunosuppressed patients.